Wells Fargo
JSPR icon

Wells Fargo’s Jasper Therapeutics JSPR Stock Holding History

Wells Fargo’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-500
Closed -$438 – 7455
2026
Q1 		$438 Sell
500
-800
-62% -$1.11K ﹤0.01% 6408
2025
Q4 		$2.38K Sell
1,300
-1,000
-43% -$2.01K ﹤0.01% 6206
2025
Q3 		$5.47K Sell
2,300
-179
-7% -$543 ﹤0.01% 6061
2025
Q2 		$13.8K Sell
2,479
-3,631
-59% -$17.9K ﹤0.01% 5870
2025
Q1 		$26.3K Sell
6,110
-1,305
-18% -$8.68K ﹤0.01% 5614
2024
Q4 		$159K Buy
7,415
+3,828
+107% +$79.7K ﹤0.01% 4928
2024
Q3 		$67.5K Sell
3,587
-138
-4% -$2.75K ﹤0.01% 5228
2024
Q2 		$84.6K Buy
3,725
+3,633
+3,949% +$87.1K ﹤0.01% 5037
2024
Q1 		$2.7K Buy
92
+31
+51% +$551 ﹤0.01% 5981
2023
Q4 		$481 Sell
61
-14
-19% -$94 ﹤0.01% 6394
2023
Q3 		$524 Sell
75
-5
-6% -$61 ﹤0.01% 6353
2023
Q2 		$1.09K Buy
80
+4
+5% +$59 ﹤0.01% 6304
2023
Q1 		$1.38K Buy
76
+49
+181% +$906 ﹤0.01% 6297
2022
Q4 		$130 Hold
27
– – ﹤0.01% 6735
2022
Q3 		$0 Buy
27
+1
+4% +$18 ﹤0.01% 7015
2022
Q2 		$0 Buy
26
+1
+4% +$28 ﹤0.01% 7158
2022
Q1 		$1K Hold
25
– – ﹤0.01% 6813
2021
Q4 		$2K Buy
+25
New +$2.34K ﹤0.01% 6887

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo's JSPR Position: Q2 2026 in Review

Wells Fargo sold out of Jasper Therapeutics (JSPR) in Q2 2026, closing a stake of 500 shares — an estimated $438 sold.

Wells Fargo first reported a position in JSPR in Q4 2021 and held it in 18 quarters. The position peaked at $159K in Q4 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Wells Fargo reported no remaining Jasper Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Wells Fargo sold 500 Jasper Therapeutics shares in Q2 2026, an estimated $438.
  • Wells Fargo first reported a position in Jasper Therapeutics in Q4 2021 and held it in 18 quarters.
  • Wells Fargo's Jasper Therapeutics position peaked at $159K in Q4 2024.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.